IL-31, itch and hematological malignancies

Clinical and Molecular Allergy

Eleonora Di Salvo¹  Alessandro Allegra²  Sebastiano Gangemi³  Marco Casciaro³ 

[1] Department of Veterinary Sciences, University of Messina, 98168, Messina, Italy;Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, 98125, Messina, Italy;School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, 98125, Messina, Italy;

关键词: IL-31;    IL-33;    Itch;    Pruritus;    Malignancies;    Cancer;    Cytokines;    Skin;   

DOI  :  10.1186/s12948-021-00148-7

来源: Springer

【 摘 要 】

Pruritus is one of the most common symptoms experienced by neoplastic patients. The pathogenesis of neoplastic itch is complex and multifactorial and could be due to an unbalanced production of humoral mediators by altered immune effector cells. IL-31 is a pro-inflammatory cytokine produced by CD4 + T helper cells. The aim of this review was to evaluate the role of this Th2 cytokine and its receptor IL-31RA, in the onset of neoplastic pruritus. We analysed scientific literature looking for the most relevant original articles linking IL-31to itch in oncologic diseases. Interleukin-31 seems to be a main itch mediator in several hematologic disease such as Cutaneous T cells lymphomas. In these patients IL-31 was positively linked to itch level, and IL-31 matched with disease stage. IL-31 seems to play an important role in the signalling pathway involved in pruritus, but it is also suggested to play a proinflammatory and immunomodulatory role which could play a part in the progression of the neoplastic disease. Further studies will be fundamental in facing pruritus in oncologic patients, since this problem compromise their quality of life worsening an already critic picture.

【 授权许可】

CC BY